The Rejuvenation Roadmap

August 27, 2024

• Added Trudiagnostics/Wildhealth:
  • Ketamine-Epigenetic Aging
• Added Trudiagnostics/SRW Laboratories:
  • SRW Cell System
• Added Trudiagnostics/Extended Longevity:
  • Extended Longevity Protocol
• Added Trudiagnostics/Big Bold Health Inc.:
  • HTB Rejuvenate (polyphenol supplement)
• Added Trudiagnostics:
  • AC-11 (Cat’s claw extract) Supplment
  • Hyperbaric Oxygen Therapy
  • Sleep Supplement-Circadian Wellness sleep SL strip
  • Peak Human Labs Calorie Mimetic Supplement
  • Quercetin and Dasatinib

August 19, 2024

• Added Gain Therapeutics:
  • GT-02287 (Parkinson’s Disease)
  • GT-02287 (Dementia with Lewy bodies/Alzheimer’s)
  • GT02329 (Gaucher’s Disease)
  • Allosteric GLB1 regulator (GM1 Gangliosides)
  • Allosteric GALC regulator (Krabbe Disease)
  • Allosteric regulation of ATT (Alpha-1 Antitrypsin Deficiency)
• Added Pelage Pharmacueticals:
  • PP405 an MPC inhibitor
• Added Yuvan Research:
  • E5 (Alternate species plasma X-change)
• Added Eperium Bio Inc.:
  • Sarcopenia/ Muscle Regeneration(MF-NCE1)
  • Fibrosis/IPF (MF-300)
  • Spinal Muscular Atrophy (SMA) MF-300

August 15, 2024

• Updated Beiwe Health:
  • BEI-258 (Human Longevity)
  • BEI-595(Glioblastoma)
  • BEI-174 Analogs (Healthspan)
• Added MDI Therapeutics:
  • MDI-2517 (for systemic sclerosis and interstitial lung disease)
• Added BioAge Labs:
  • BGE-100 (metabolic disease & neuroinflammation)
  • BGE-105-005
• Added Minicircle:
  • MINI-002 Klotho Gene Therapy
  • MINI-001 Follastatin Gene Therapy NCT06411366

July 24, 2024

• Advanced Insilico Medicine MAT2A inhibitor, USP1 inhibitor, QPCTL inhibitor, and KAT6 inhibitor to phase 1.
• Insilico Medicine 3CLpro advanced to Phase 1 completion.
• Insilico Medicine PHD1/2 inhibitor moved to phase 2 for IBD treatment.
• Insilico Medicine INS018_055 moved to phase 2 for IPF.

December 4, 2023

• Added Ta Sciences:
  • TA-65
• Added TAmiRNA:
  • osteomiR®
  • HepatomiR
  • ToximiR
  • SenomiR
  • ThrombomiR
• Updated Rejuvenate Bio:
  • RBJ-01
  • RBJ-02
  • RBJ-03

October 9, 2023

• Updated Insilico Medicine:
  • Target X Inhibitor (Fibrotic diseases treatment)
  • 3CLpro Inhibitor (COVID-19 treatment
  • KAT6 Inhibitor (Breast Cancer treatment)
  • MAT2A Inhibitor (Cancer treatment)
  • USP1 Inhibitor (Cancer treatment)
  • QPCTL Inhibitor (Cancer treatment) (Co-developed with Fosun)
  • PHD1/2 Inhibitor (Anemia of CKD treatment)
  • PHD1/2 Inhibitor (IBD treatment)
• Added Clock.Bio
  • (No Current Product)
• Added Rejuvenation Technologies:
  • RTI-LNG1 (IPF)
  • RTI-LNG1(Non IPF)
  • RTI-LIV(Compensated Cirrhosis)
  • RTI-LIV (Alcoholic Hepatitis)
  • RTI-IMM (NA1)
  • RTI-IMM (NA2)

May 31, 2023

• Added Elysium Health:
  • Basis
  • TIME-A
  • Basis-BES2T BET
  • Basis-NAFLD
  • EH301
  • Basis (15BSHE)
  • Basis
  • NR
  • Basis EH301 No-ALS
  • Basis-AKI
  • Basis BAKIS
  • Basis Menopause
  • NR-COPD
  • NR-Brain Vascular Health
• Added Endogena Therapeutics:
  • EA-2353 Retinitis Pigmentosa
  • EA-2351
  • Endogena IPF
  • Endogena Hematopoietic Recovery
  • Endogena Neurodegeneration
• Added Epimorphy LLC (MyDNAge):
  • myDNAge
• Added Equator Therapeutics:
  • Mitochondrial thermogenesis promotion
• Added Fauna Bio:
  • Small molecule drug development
• Added Fountain Therapeutics:
  • Small molecule drug development
• Added GEn1E Lifesciences:
  • Gen-1124
• Added Genescient
• Added GenFlow Biosciences
  • GF-1002
• Updated GenSight Biologics:
  • GS011 LHON-ND4
  • S030 (RP)

May 2, 2023

• Added CellVie: Mitochondrial Transplantation
• Added Centaura: Artificial Chromosome
• Added Cerevance:
  • CVN424
  • CVN766
  • CVN293
  • CVN398
  • Target-18
• Added Cleara Biotech:
  • CL04177
  • CL04183
• Added Covalent Bioscience:
  • Cardizyme
  • Alzyme-Tauzyme
• Added Cyclo Therapeutics:
  • Trappsol Cyclo NPC
  • Trappsol Cyclo Alzheimer’s
• Added Cytegen: mitochondrial stimulators
• Added Deciduos Therapeutics: senolytics
• Added Dorian Therapeutics: senoblockers
• Added Eidos Therapeutics: acoramidis (AG10) (Phase 3 Completed)
• Added Elastrin Therapeutics: DESTINED
• Updated CohBar Inc:
  • CB5138 (Preclinical in vitro)
  • CB4211 (Obesity) (Phase 1 Completed)
  • CB4211 (NASH) (Phase 1 Completed)
• Updated ChromaDex: Niagen (Phase 1 Completed)

May 1, 2023

• Added ByoMass Therapeutics: selective TGF-beta inhibitors
• Added Calico:
  • ABBV-CLS-579 (PTPN2 inhibitor)
  • ABBV-CLS-484
  • ABBV-CLS-7262 (ALS)
  • ABBV-CLS-7262 (VWM)
• Added Cambrian Biopharma:
  • CAM-9782
  • CAM-5746
  • CAM-5746
  • ATX-304
  • VTA-300
  • VTA-100
  • CAM-5131
  • CAM-5132
  • CAM-1108
  • CAM-7520
  • CAM-6019
  • CAM-4628
  • CAM-7276

April 8, 2023

• Updated Unity Biotech UBX1325

March 28, 2023

• Updated Atropos Therapeutics: Senostimulators/Senosuppressors
• Added Beiwe Health: BEI-101
• Added Beiwe Health: BEI-103
• Added Beiwe Health: BEI-105
• Added BHB Therapeutics: Beta Hydroxy Butyrate
• Updated BioAge Labs: BGE-105
• Updated BioAge Labs: NLRP3
• Updated BioAge Labs: BGE-117
• Added BioChange ltd: Extracellular matrix support matierials
• Updated Biophytis: Sarconeos (BIO101)
• Updated Biophytis: Sarconeos (BIO101)
• Updated Biophytis: Macuneos (BIO 201) Wet/Dry Macular Degeneration
• Updated Biophytis: Macuneos (BIO201) Stargardt’s Macular Degeneration
• Updated Biosplice (was Samumed): Cirtuvivint (SM08502) mCRPC,CRC,NSCLC
• Updated Biosplice (was Samumed): Cirtuvivint (SM08502) select heme malignancies
• Updated Biosplice (was Samumed): Cirtuvivint (SM08502) additional solid tumors
• Updated Biosplice (was Samumed): DYRK 1A targeting molecule
• Updated Biosplice (was Samumed): CLK2 inhibitor
• Updated Biosplice (was Samumed): CLK3
• Updated Biosplice (was Samumed): Pan-CLK/DYRK (intra-articular injection) SM04690
• Updated Biosplice (was Samumed): SM04690 Osteoarthritis of the hip
• Updated Biosplice (was Samumed): SM04690 Osteoarthritis of the shoulder Phase 3
• Updated Biosplice (was Samumed): SM04690 Osteoarthritis of the shoulder Preclinical In Vitro
• Updated Biosplice (was Samumed): DYRK 1A targeting molecule
• Added BioViva: CMV Gene Therapy to increase follistatin and telomerase
• Added Brainstorm Cell Therapeutics: NurOwn® for the treatment of ALS
• Added Brainstorm Cell Therapeutics: NurOwn® for progressive MS
• Added Brainstorm Cell Therapeutics: NurOwn® for progressive Huntington’s disease
• Added Brainstorm Cell Therapeutics: NurOwn® for progressive NurOwn® for Parkinson’s disease
• Added Brainstorm Cell Therapeutics: NurOwn® for progressive for Autism Spectrum Disorder

February 23, 2023

• Added Amprion: Protein Misfolding Cyclic Amplification (PMCA) Device
• Added Aspen Neuroscience: ANPD001
• Added Aspen Neuroscience: ANPD002
• Added Athersys Inc. : MultiStem for Ishemic Stroke
• Added Athersys Inc. : MultiStem for Spinal Cord Injury
• Added Athersys Inc. : Multistem for Multiple Sclerosis
• Added Athersys Inc. : Traumatic Brain Injury
• Added Insilico Medicine: INS018_055 Phase1, discovered to treat Idiopathic Pulmonary Fibrosis
• Added Insilico Medicine: INS018_055 In vitro, preclinical to determine effects on kidney fibrosis
• Added Insilico Medicine: INS018_055 In vitro, preclinical to determine effects on skin fibrosis also known as scleroderma

February 22, 2023

• Updated Alkahest: AKST4290 WetAMD
• Updated Alkahest: AKST4290 Parkinson’s Disease
• Updated Alkahest: AKST4290 Inflammatory Disease
• Updated Alkahest: AKST/GRF6019 Alzheimer’s Disease Mild to Moderate
• Updated Alkahest: AKST/GRF6019/6021 Alzheimer’s Severe
• Updated Alkahest: GRF 6021 Parkinsons with cognitive impairment
• Updated Alkahest: GRF 6021 postoperative recovery
• Updated Alkahest: AKST1210
• Added Altoida: NMI (Neuro Motor Index)
• Added Altos Labs: Cellular reprogramming technology

February 15, 2023

• Moved biomarkers to biomarker aging category and entered not applicable under all biomarker products.
• Recategorized items in passed preclinical

February 14, 2023

• Added new biomarkers of aging category to better group biomarkers together in one place

February 6, 2023

• Added Alector: AL001-Frontotemporal dementia (FTD) in granulin mutation
• Added Alixia
• Added Tranquis Therapeutics: TQS-168
• Added Tranquis Therapeutics: TQS-621
• Added Vaxxinity (was United Neuro.): UB-311
• Added Vaxxinity: Anti-tau product
• Added Vaxxinity: UB-312
• Added Vaxxinity: UB-313
• Added Vaxxinity: VXX-401
• Added YouthBio Therapeutics
• Added Yuva Biosciences

27 January 2023

• Added ADx Neurosciences
• Added Aelan Cell Technologies
• Updated Aeovian
• Updated Age Labs
• Updated AgeX Ther. / Reverse bio for each pipeline item
• Added Alchemab Therapeutics

12 January 2023

• Added Aeovian Pharmaceuticals
• Added Age Labs
• Updated Amazentis Study NCT04783207

11 January 2023

• Added 1E Therapeutics
• Added 5Alarmbio
• 712North no longer operating
• Added Fujirebio NCT03174938 Alzheimer’s disease detection- Fujirebio acquired Aelan Cell Technologies

3 January 2022

• Updated CNIO with two additional studies on Telomerase.

14 Dec 2022

• Updated NMN segment with clinical trial reports from Washington University School of Medicine NCT03151239 and NCT04571008,  added Phase not applicable
• Added EffePharm LTD NMN study completed March 2021 NCT04228640

5 Dec 2022

• Updated Bioage with phase 1b clinical trial results

22 July 2022

• Updated Underdog Pharmaceuticals name to Cyclarity

20 February 2022

• Unity updated with new clinical trial end dates.

2 December 2021

• Longeveron updated with new trial.

12 November 2021

• Unity updated with clinical trial results.

27 October 2021

• Rejuvenate Bio added.

20 October 2021

• CohBar Inc added.

7 October 2021

• Repair Biotechnologies added.

5 October 2021

• Updated Unity with clinical trial update.

25 September 2021

• Updated Underdog with new funding.

21 September 2021

• Updated Elevian with new funding.

20 September 2021

• Updated Alkahest with new candidates, clinical trials, and clinical trial results.

19 September 2021

• Updated Gensight with new Phase 3 clinical trial results & availability.
• Updated Atropos to include current plans.
• Updated SENSICA with new funding.
• Updated Longeveron with new trial results.
• Updated Immunic with new funding.

18 September 2021

• Changed name of Proteostasis to Yumanity and updated program status.
• Updated Stealth Bio with new drug application.

17 September 2021

• Changed name of Ichor Therapeutics to Ichor Life Sciences.
• Updated Leucadia with planned clinical trial start date.
• Updated Underdog with product name & website link.
• Updated Attralus with lead product & additional financing.

8 September 2021

• Updated Rejevenie with name of product & clinical trial status.
• Updated BioAge with new clinical trials & drug candidates.

27 August 2021

• Samumed name changed to Biosplice and updated with Phase 2b results & new indication.

24 August 2021

• Updated Longeveron with Phase 2b frailty trial results & availability.

6 August 2021

• Updated Biophytis to show completed Phase 2b & study results link.

29 July 2021

• Updated Scholar Rock with completed Phase 2 trial & results.
• Updated Adicet with discontinuation of RTB101.

28 July 2021

• Updated the Conboy Lab with links to new study results & new start-up.

27 July 2021

• Updated Longeveron with study results and link to clinical trials.
• Updated BlueRock to include link to clinical trial.

26 July 2021

• Updated SIWA to include drug candidate & indication.
• Moved Intervene Immune to Phase 2 & included clinical study link.
• Upadted LyGenesis to include links to preclinical study results.

23 July 2021

• Updated Stealth Bio with links to new results, new drug candidate & move to Phase 3.

22 July 2021

• Updated Mitotech to include results of Phase 2b/3 clinical trial and other indications.

21 July 2021

• Updated Denali to include completion of Phase 1b and additional candidates.
• Updated Alterity to include link to Phase 1 results & Orphan Drug designation.
• Updated Animal Biosciences to include link to new website.
• Updated Continuum Biosciences to include link to new website.
• Updated Amazentis to include links to clinical trials & launch of first product.

15 July 2021

• Updated Underdog to include new funding round & regulatory meeting.
• Changed Aurora company name to Attralus and added links to clinical data & lead product candidates.

14 July 2021

• Updated Iduna to include a license from Harvard & related study link.
• Updated Proclara to include a link to Phase 1B study results.
• Updated Selphagy to include new drug and study link.

12 July 2021

• Updated Oisin with lead candidate, indication and funding level.
• Updated Mayo clinic with link to fisetin clinical trials.
• Updated Scripps Research Institute with link to clinical trials.

9 July 2021

• Updated Chromadex to include moving to Phase 2 and link to clinical trials.
• Updated Turn.Bio to include further funding and link to published study.

8 July 2021

• Updated Telocyte to include moving into preclinical in vivo large animal models.
• Updated Unity UBX1325 to include Phase 1 results and Phase 2 initiation.

7 July 2021

• Updated Grifols to include Phase 3 and opening of first clinic.

30 June 2021

• Updated Gensight to include extended phase 3 data.

18 March 2021

• Immunic Therapeutics conducts Phase 1 trial for intestinal barrier dysfunction

13 March 2021

• BioAge conducts Phase 2a human trial for unexplained anemia

8 January 2021

• LyGenesis is approved for Phase 2A trial for patients with end-stage liver disease

12 December 2020

• Gensight improves vision in Phase 3 trial for mitochondrial gene therapy

25 November 2020

• Elevian receives $15 million of equity funding for GDF11

13 October 2020

• Unity launches phase 1 study of UBX1325 in patients with diabetic macular edema

24 September 2020

• Added alpha-ketoglutarate
• Marked Unity UBX0101

25 August 2020

• Added new publication to Jumpstart Fertility

18 August 2020

• Unity UBX0101 updated following Phase 2 trial results

10 July 2020

• Alterity Therapeutics added
• Iduna Therapeutics added

26 May 2020

• Updated NMN to include small phase 1 human trial

28 January 2020

• Proteostasis Therapeutics added
• Revel Pharmaceuticals added
• SIWA Therapeutics added

23 January 2020

• BlueRock added
• Denali added
• GenSight added
• Intervene Immune updated

22 January 2020

• Atropos Therapeutics added
• Aurora Bio added
• Biophytis added

13 January 2020

• Stealth Biotherapeutics added

19 November 2019

• Underdog added

18 November 2019

• resTORbio moved back to phase 2

15 November 2019

• Rejenevie added
• Mitotech added

14 November 2019

• Longeveron added
• Alkahest added

22 September 2019

• Updated Dasatinib and Quercetin at Mayo with second phase 1 human trial info
• Urolotin A by Amazentis added

24 July 2019

• Added Turn.bio – OSKMLN

18 June 2019

• UBX0101 by Unity Biotechnology moved to Phase 2

05 June 2019

• Samumed moved to Phase 3

05 Apr 2019

• Added Mayo Clinic – Fisetin
• Added Elevian – GDF11
• Added Unity – UBX1967
• Added Unity – UBX0101
• J147 moved to Phase 1

19 Mar 2019

• resTORbio RTB101 moved to phase 3 following successful phase 2 and 2b trials

11 Mar 2019 

• Updated Scripps Institute to Phase 2

25 Jan 2019

• Updated Scripps Institute to Phase 1

03 Dec 2018